Advances of Antibiotic Alternatives

doi:10.11924/j.issn.1000-6850.2014-1628

Abstract

Abstract: The persistence and spread of antibiotic resistance caused by the abuse of growth- promoting antibiotics, in conjunction with the bottleneck of development of new antibiotics, have created the dangerous prospect of ineffective therapies against bacterial diseases. In this situation, national strategies aimed at discovery and developments of effective antibiotic alternatives, especially for agricultural applications, had been encouraged. This article overviewed eight kinds of antibiotic alternatives, including antibacterial vaccines, immunomodulatory agents, bacteriophages and their lysins, antimicrobial peptides, pro-, pre- and synbiotics, plant extracts, inhibitors targeting pathogenicity and feed enzymes. The progress of research and development, problems and prospects of antibiotic alternatives were fully discussed. Because of their limitations, veterinary antibiotic alternatives so far can not substitute for antibiotics. Only to establish a scientific monitoring system and continue to develop improved antibiotic alternatives can we reduce the negative effects of antibiotic abuse, ensure the safety of animal- derived food, thus achieve the green and healthy development of animal husbandry.

郝海红, 谢书宇, 王旭 and 袁宗辉. Advances of Antibiotic Alternatives[J]. Chinese Agricultural Science Bulletin, 2014, 30(35): 97-106.

References

[1] Casewell M, Friis C, Marco E, et al. The European ban on growthpromoting antibiotics and emerging consequences for human and animal health[J]. J Antimicrob Chemother,2003,52(2):159-161.
[2] Millet S, Maertens L. The European ban on antibiotic growth promoters in animal feed: from challenges to opportunities[J]. Vet J, 2011,187(2):143-144.
[3] Hu S, Ma H, Wu Y, et al. A vaccine candidate of attenuated genotype VII Newcastle disease virus generated by reverse genetics [J]. Vaccine,2009,27(6):904-910.
[4] Buckley A M, Wang J, Hudson D L, et al. Evaluation of liveattenuated Salmonella vaccines expressing Campylobacter antigens for control of C. jejuni in poultry[J]. Vaccine,2010,28(4):1094-1105.
[5] Crouch C F, Withanage G S, de Haas V, et al. Safety and efficacy of a maternal vaccine for the passive protection of broiler chicks against necrotic enteritis[J]. Avian Pathol,2010,39(6):489-497.
[6] Francis D H, Willgohs J A. Evaluation of a live avirulent Escherichia coli vaccine for K88 + , LT + enterotoxigenic colibacillosis in weaned pigs[J]. Am J Vet Res,1991,52(7):1051- 1055.
[7] Song Y, La T, Phillips N D, et al. A reverse vaccinology approach to swine dysentery vaccine development[J]. Vet Microbiol,2009,137(1/ 2):111-119.
[8] Ruan X, Liu M, Casey T A, et al. A tripartite fusion, FaeG-FedF-LT (192)A2:B, of enterotoxigenic Escherichia coli (ETEC) elicits antibodies that neutralize cholera toxin, inhibit adherence of K88 (F4) and F18 fimbriae, and protect pigs against K88ac/heat- labile toxin infection[J]. Clin Vaccine Immunol,2011,18(10):1593-1599.
[9] Thacker E L. Immunomodulators, immunostimulants, and immunotherapies in small animal veterinary medicine[J]. Vet Clin North Am Small Anim Pract,2010,40(3):473-483.
[10] Bricknell I, Dalmo R A. The use of immunostimulants in fish larval aquaculture[J]. Fish Shellfish Immunol,2005,19(5):457-472.
[11] Lemire J A, Harrison J J, Turner R J. Antimicrobial activity of metals: mechanisms, molecular targets and applications[J]. Nat Rev Microbiol,2013,11(6):371-384.
[12] Gans J, Wolinsky M, Dunbar J. Computational improvements reveal great bacterial diversity and high metal toxicity in soil[J]. Science, 2005, 309 (5739): 1387-1390.
[13] Gertsch J, Viveros-Paredes J M, Taylor P. Plant immunostimulantsScientific paradigm or myth?[J]. J Ethnopharmacol,2011,136(3): 385-391.
[14] O'Flaherty S, Ross R P, Coffey A. Bacteriophage and their lysins for elimination of infectious bacteria[J]. FEMS Microbiol Rev, 2009,33(4):801-819.
[15] Johnson R P, Gyles C L, Huff W E, et al. Bacteriophages for prophylaxis and therapy in cattle, poultry and pigs[J]. Anim Health Res Rev,2008,9(2):201-215.
[16] Huff W E, Huff G R, Rath N C, et al. Alternatives to antibiotics: utilization of bacteriophage to treat colibacillosis and prevent foodborne pathogens[J]. Poult Sci,2005,84(4):655-659.
[17] Pirnay J P, De Vos D, Verbeken G, et al. The phage therapy paradigm: pret- a- porter or sur- mesure?[J]. Pharm Res,2011,28(4): 934-937.
[18] Allen H K, Levine U Y, Looft T, et al. Treatment, promotion, commotion: antibiotic alternatives in food- producing animals[J]. Trends Microbiol,2013,21(3):114-119.
[19] Merril C R, Biswas B, Carlton R, et al. Long- circulating bacteriophage as antibacterial agents[J]. Proc Natl Acad Sci U S A, 1996,93(8):3188-3192.
[20] Smith H W, Huggins M B. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics[J]. J Gen Microbiol, 1982, 128 (2): 307- 318.
[21] Brussow H. Bacteriophage: Genetics and Microbiology[A]. Phage therapy: the Western perspective[M]. McGrath, S., Ed. Caister Academic Press,2007:159-192.
[22] Carlton R M. Phage therapy: past history and future prospects[J]. Arch Immunol Ther Exp (Warsz), 1999, 47 (5): 267-274.
[23] Berchieri A, Jr., Lovell M A, Barrow P A. The activity in the chicken alimentary tract of bacteriophages lytic for Salmonella typhimurium[J]. Res Microbiol, 1991, 142 (5): 541-549.
[24] Callaway T R, Edrington T S, Brabban A, et al. Evaluation of phage treatment as a strategy to reduce Salmonella populations in growing swine[J]. Foodborne Pathog Dis, 2011, 8 (2): 261-266.
[25] Burrowes B, Harper D R, Anderson J, et al. Bacteriophage therapy: potential uses in the control of antibiotic- resistant pathogens[J]. Expert Rev Anti Infect Ther, 2011, 9 (9): 775-785.
[26] Ralston D J, Baer B S, Lieberman M, et al. Virolysin: a virusinduced lysin from staphylococcal phage lysates[J]. Proc Soc Exp Biol Med, 1955, 89 (4): 502-507.
[27] Low L Y, Yang C, Perego M, et al. Structure and lytic activity of a Bacillus anthracis prophage endolysin[J]. J Biol Chem, 2005, 280 (42): 35433-35439.
[28] Fenton M, Ross P, McAuliffe O, et al. Recombinant bacteriophage lysins as antibacterials[J]. Bioeng Bugs, 2010, 1 (1): 9-16.
[29] Fischetti V A. Bacteriophage lytic enzymes: novel anti- infectives [J]. Trends Microbiol, 2005, 13 (10): 491-496.
[30] Loeffler J M, Djurkovic S, Fischetti V A. Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia[J]. Infect Immun, 2003, 71 (11): 6199-6204.
[31] O'Flaherty S, Coffey A, Meaney W, et al. The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including methicillin- resistant Staphylococcus aureus[J]. J Bacteriol, 2005, 187 (20): 7161-7164.
[32] Yoong P, Schuch R, Nelson D, et al. Identification of a broadly active phage lytic enzyme with lethal activity against antibioticresistant Enterococcus faecalis and Enterococcus faecium[J]. J Bacteriol, 2004, 186 (14): 4808-4812.
[33] Courchesne N M, Parisien A, Lan C Q. Production and application of bacteriophage and bacteriophage- encoded lysins[J]. Recent Pat Biotechnol, 2009, 3 (1): 37-45.
[34] Loeffler J M, Nelson D, Fischetti V A. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase [J]. Science, 2001, 294 (5549): 2170-2172.
[35] Rodriguez- Rubio L, Martinez B, Donovan D M, et al. Bacteriophage virion- associated peptidoglycan hydrolases: potential new enzybiotics[J]. Crit Rev Microbiol,2013,39(4):427- 434..
[36] Rodriguez L, Martinez B, Zhou Y, et al. Lytic activity of the virionassociated peptidoglycan hydrolase HydH5 of Staphylococcus aureus bacteriophage vB_SauS- phiIPLA88[J]. BMC Microbiol, 2011,11:138.
[37] Takac M, Blasi U. Phage P68 virion-associated protein 17 displays activity against clinical isolates of Staphylococcus aureus[J]. Antimicrob Agents Chemother, 2005, 49 (7): 2934-2940.
[38] Rashel M, Uchiyama J, Takemura I, et al. Tail-associated structural protein gp61 of Staphylococcus aureus phage phi MR11 has bifunctional lytic activity[J]. FEMS Microbiol Lett, 2008, 284 (1): 9-16.
[39] Caldentey J, Bamford D H. The lytic enzyme of the Pseudomonas phage phi 6. Purification and biochemical characterization[J]. Biochim Biophys Acta, 1992, 1159 (1): 44-50.
[40] Lavigne R, Briers Y, Hertveldt K, et al. Identification and characterization of a highly thermostable bacteriophage lysozyme [J]. Cell Mol Life Sci, 2004, 61 (21): 2753-2759.
[41] Paul V D, Rajagopalan S S, Sundarrajan S, et al. A novel bacteriophage Tail- Associated Muralytic Enzyme (TAME) from Phage K and its development into a potent antistaphylococcal protein[J]. BMC Microbiol, 2001, 11: 226.
[42] Rodriguez- Rubio L, Martinez B, Rodriguez A, et al. Enhanced staphylolytic activity of the Staphylococcus aureus bacteriophage vB_SauS- phiIPLA88 HydH5 virion- associated peptidoglycan hydrolase: fusions, deletions, and synergy with LysH5[J]. Appl Environ Microbiol, 2012, 78 (7): 2241-2248.
[43] Leonard B C, Affolter V K, Bevins C L. Antimicrobial peptides: agents of border protection for companion animals[J]. Vet Dermatol, 2012, 23 (3): 177-e136.
[44] Bierbaum G, Sahl H G. Lantibiotics: mode of action, biosynthesis and bioengineering[J]. Curr Pharm Biotechnol, 2009, 10 (1): 2-18.
[45] Cotter P D, Hill C, Ross R P. Bacteriocins: developing innate immunity for food[J]. Nat Rev Microbiol, 2005, 3 (10): 777-788.
[46] Field D, Hill C, Cotter P D, et al. The dawning of a 'Golden era' in lantibiotic bioengineering[J]. Mol Microbiol, 2011, 78 (5): 1077- 1087.
[47] Lee H, Kim H Y. Lantibiotics, Class I Bacteriocins from the Genus Bacillus[J]. J Microbiol Biotechnol,2011,21(3):229-235.
[48] Piper C, Draper L A, Cotter P D, et al. A comparison of the activities of lacticin 3147 and nisin against drug- resistant Staphylococcus aureus and Enterococcus species[J]. J Antimicrob Chemother,2009,64(3):546-551.
[49] Kramer N E, van Hijum S A, Knol J, et al. Transcriptome analysis reveals mechanisms by which Lactococcus lactis acquires nisin resistance[J]. Antimicrob Agents Chemother,2006,50(5):1753-1761.
[50] del Castillo F J, del Castillo I, Moreno F. Construction and characterization of mutations at codon 751 of the Escherichia coli gyrB gene that confer resistance to the antimicrobial peptide microcin B17 and alter the activity of DNA gyrase[J]. J Bacteriol, 2001,183(6):2137-2140.
[51] Draper L A, Grainger K, Deegan L H, et al. Cross- immunity and immune mimicry as mechanisms of resistance to the lantibiotic lacticin 3147[J]. Mol Microbiol,2009,71(4):1043-1054.
[52] Sun Z, Zhong J, Liang X, et al. Novel mechanism for nisin resistance via proteolytic degradation of nisin by the nisin resistance protein NSR[J]. Antimicrob Agents Chemother,2009,53 (5):1964-1973.
[53] Nocek B, Tikhonov A, Babnigg G, et al. Structural and functional characterization of microcin C resistance peptidase MccF from Bacillus anthracis[J]. J Mol Biol, 2012, 420 (4-5): 366-383.
[54] Gaggia F, Mattarelli P, Biavati B. Probiotics and prebiotics in animal feeding for safe food production[J]. Int J Food Microbiol, 2010, 141 Suppl 1: S15-28.
[55] Balish E, Wagner R D. Probiotic bacteria for prophylaxis and therapy of candidiasis[J]. Rev Iberoam Micol, 1998, 15 (4): 261- 264.
[56] Frana T S, Carlson S A, Rauser D C, et al. Effects of microcin 24- producing Escherichia coli on shedding and multiple-antimicrobial resistance of Salmonella enterica serotype Typhimurium in pigs[J]. Am J Vet Res, 2004, 65 (12): 1616-1620.
[57] Borriello S P, Hammes W P, Holzapfel W, et al. Safety of probiotics that contain lactobacilli or bifidobacteria[J]. Clin Infect Dis, 2003, 36 (6): 775-780.
[58] Gibson G R, Probert H M, Loo J V, et al. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics[J]. Nutr Res Rev, 2004, 17 (2): 259-275.
[59] de Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics [J]. Adv Biochem Eng Biotechnol, 2008, 111: 1-66.
[60] Andersson H, Asp N-G, Bruce A, et al. Health effects of probiotics and prebiotics: a literature review on human studies[J]. Scand J Nutr, 2001, 45: 58-75.
[61] Modesto M, D'Aimmo M R, Stefanini I, et al. A novel strategy to select Bifidobacterium strains and prebiotics as natural growth promoters in newly weaned pigs[J]. Livestock Science, 2009, 122 (2-3): 248-258.
[62] Kolida S, Gibson G R. Synbiotics in health and disease[J]. Annu Rev Food Sci Technol, 2011, 2: 373-393.
[63] Hashemi S R, Davoodi H. Herbal plants and their derivatives as growth and health promoters in animal nutrition[J]. Vet Res Commun, 2011, 35 (3): 169-180.
[64] Abreu A C, McBain A J, Simoes M. Plants as sources of new antimicrobials and resistance- modifying agents[J]. Nat Prod Rep, 2012, 29 (9): 1007-1021.
[65] Simoes M, Bennett R N, Rosa E A. Understanding antimicrobial activities of phytochemicals against multidrug resistant bacteria and biofilms[J]. Nat Prod Rep, 2009, 26 (6): 746-757.
[66] Stavri M, Piddock L J, Gibbons S. Bacterial efflux pump inhibitors from natural sources[J]. J Antimicrob Chemother, 2007, 59 (6): 1247-1260.
[67] Harvey A L. Natural products in drug discovery[J]. Drug Discov Today, 2008, 13 (19-20): 894-901.
[68] Manzanilla E G, Perez J F, Martin M, et al. Effect of plant extracts and formic acid on the intestinal equilibrium of early-weaned pigs [J]. J Anim Sci, 2004, 82 (11): 3210-3218.
[69] Namkung H, Li M, Gong J, et al. Impact of feeding blends of organic acids and herbal extracts on growth performance, gut microbiota and digestive function in newly weaned pigs[J]. Canadian Journal of Animal Science,2004,84:697-704.
[70] Zanchi R, Canzi E, Molteni L, et al. Effect of Camellia sinensis L.whole plant extract on piglet intestinal ecosystem[J]. Ann Microbiol, 2008,58:147-152.
[71] Borovan L. Plant alkaloids enhance performance of animals and improve the utilizability of amino acids (in Czech) [J]. Krmivarstvi, 2004, 6: 36-37.
[72] Tatara M R, Sliwa E, Dudek K, et al. Aged garlic extract and allicin improve performance and gastrointestinal tract development of piglets reared in artificial sow[J]. Ann Agric Environ Med,2008,15 (1): 63-69.
[73] Oetting L L, Utiyama C E, Giani P A, et al. Effects of herbal extracts and antimicrobials on apparent digestibility, performance, organs morphometry and intestinal histology of weanling pigs[J]. Brazilian Journal of Animal Science,2006,35:1389-1397.
[74] Costa L B, Panhoza Tse M L, Miyada V S. Herbal extracts as alternatives to antimicrobial growth for weanling pigs[J]. Brazilian Journal of Animal Science, 2007, 36: 589-595.
[75] Hashemi S R, Davoodi H. Phytogenics as new class of feed additive in poultry industry[J]. J Anim Vet Adv, 2010, 9: 2955-2304.
[76] Yang Y, Iji P A, Choct M. Dietary modulation of gut microflora in broiler chickens: a review of the role of six kinds of alternatives to in-feed antibiotics[J]. Worlds Poult Sci, 2009, 65: 97-114.
[77] Sarica S, Ciftci A, Demir E, et al. Use of an antibiotic growth promoter and two herbal natural feed additives with and without exogenous enzymes in wheat based broiler diets[J]. S Afr J Anim Sci, 2005, 35: 61-72.
[78] Anadon A, Abroix Arzo M, Bories G, et al. Opinion of the FEEDAP Panel on the safety and efficacy of the product Farmatan for rabbits and piglets[J]. The EFSA Journal, 2005, 222: 1-20.
[79] Giannenas A I, Florou- Paneri P, Papazahariadou M, et al. Dietary oregano essential oil supplementation on performance of broilers challenged with Eimeria tenella[J]. Arch Anim Nutr, 2003, 57: 99- 106.
[80] Swift S, Downie J A, Whitehead N A, et al. Quorum sensing as a population- density- dependent determinant of bacterial physiology [J]. Adv Microb Physiol, 2001, 45: 199-270.
[81] Parsek M R, Val D L, Hanzelka B L, et al. Acyl homoserine-lactone quorum- sensing signal generation[J]. Proc Natl Acad Sci U S A, 1999, 96 (8): 4360-4365.
[82] Amara N, Krom B P, Kaufmann G F, et al. Macromolecular inhibition of quorum sensing: enzymes, antibodies, and beyond[J]. Chem Rev, 2011, 111 (1): 195-208.
[83] Kalia V C, Purohit H J. Quenching the quorum sensing system: potential antibacterial drug targets[J]. Crit Rev Microbiol, 2011, 37 (2): 121-140.
[84] Bjarnsholt T, Givskov M. Quorum- sensing blockade as a strategy for enhancing host defences against bacterial pathogens[J]. Philos Trans R Soc Lond B Biol Sci, 2007, 362 (1483): 1213-1222.
[85] Bjarnsholt T, Givskov M. Quorum sensing inhibitory drugs as next generation antimicrobials: worth the effort?[J]. Curr Infect Dis Rep, 2008, 10 (1): 22-28.
[86] Resch A, Rosenstein R, Nerz C, et al. Differential gene expression profiling of Staphylococcus aureus cultivated under biofilm and planktonic conditions[J]. Appl Environ Microbiol, 2005, 71 (5): 2663-2676.
[87] Mai G T, McCormack J G, Seow W K, et al. Inhibition of adherence of mucoid Pseudomonas aeruginosa by alginase, specific monoclonal antibodies, and antibiotics[J]. Infect Immun, 1993, 61 (10): 4338-4343.
[88] Hatch R A, Schiller N L. Alginate lyase promotes diffusion of aminoglycosides through the extracellular polysaccharide of mucoid Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 1998, 42 (4): 974-977.
[89] Selan L, Berlutti F, Passariello C, et al. Proteolytic enzymes: a new treatment strategy for prosthetic infections?[J]. Antimicrob Agents Chemother, 1993, 37 (12): 2618-2621.
[90] Young J A, Collier R J. Anthrax toxin: receptor binding, internalization, pore formation, and translocation[J]. Annu Rev Biochem, 2007, 76: 243-265.
[91] Shoop W L, Xiong Y, Wiltsie J, et al. Anthrax lethal factor inhibition [J]. Proc Natl Acad Sci U S A, 2005, 102 (22): 7958-7963.
[92] Moayeri M, Wiggins J F, Lindeman R E, et al. Cisplatin inhibition of anthrax lethal toxin[J]. Antimicrob Agents Chemother, 2006, 50 (8): 2658-2665.
[93] Nordfelth R, Kauppi A M, Norberg H A, et al. Small- molecule inhibitors specifically targeting type III secretion[J]. Infect Immun, 2005, 73 (5): 3104-3114.
[94] Hudson D L, Layton A N, Field T R, et al. Inhibition of type III secretion in Salmonella enterica serovar Typhimurium by smallmolecule inhibitors[J]. Antimicrob Agents Chemother, 2007, 51 (7): 2631-2635.
[95] Pinkner J S, Remaut H, Buelens F, et al. Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria[J]. Proc Natl Acad Sci U S A, 2006, 103 (47): 17897-17902.
[96] Hung D T, Shakhnovich E A, Pierson E, et al. Small- molecule inhibitor of Vibrio cholerae virulence and intestinal colonization[J]. Science, 2005, 310 (5748): 670-674.
[97] Clatworthy A E, Pierson E, Hung D T. Targeting virulence: a new paradigm for antimicrobial therapy[J]. Nat Chem Biol,2007,3(9): 541-548.
[98] Ravindran V, Son J H. Feed enzyme technology: present status and future developments[J]. Recent Pat Food Nutr Agric,2011,3(2):102- 109.
[99] Slominski B A. Recent advances in research on enzymes for poultry diets[J]. Poult Sci,2011,90(9):2013-2023.